Treating HER2-Positive Metastatic Breast Cancer: DESTINY-Breast02 and DESTINY-Breast03

The role of antibody drug conjugate DS-8201a (trastuzumab deruxtecan) in the treatment of HER2-positive metastatic breast cancer and an overview of the DESTINY-Breast02 and DESTINY-Breast03 trials.

For Younger Patients, CAR T-Cell Therapy Could Play a Role in CLL Treatment

In Cancer Caregiving, a Passion for Learning is Vital

Alleviating Pandemic-Related Anxiety Over Returning to the Clinic for Clinical Trials